On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus’s casdatifan (an investigational HIF-2α inhibitor) with Summit’s ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of this combination in clear cell renal cell carcinoma (ccRCC), including first-line […]

Summit Therapeutics Inc. on Wednesday shared updated overall survival (OS) data from its Phase 3 HARMONi study, evaluating the investigational bispecific antibody ivonescimab for treating specific forms of lung cancer. The study is evaluating ivonescimab combined with chemotherapy compared to...

Summit Therapeutics Inc (SMMT) reports robust financial health and significant progress in clinical trials, despite facing competitive and regulatory challenges.

Summit Therapeutics (SMMT) drew fresh attention after releasing updated overall survival data from its global Phase III HARMONi trial of ivonescimab plus chemotherapy, a material step in its ongoing FDA review. See our latest analysis for Summit Therapeutics. The updated HARMONi data arrives after a volatile period for Summit Therapeutics, with the share price at $14.98, a 7 day share price return of 8.87% but a 90 day share price return that declined 32.16%, and a very large 3 year total...

Summit Therapeutics (NASDAQ:SMMT) executives used the company’s latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail the company’s cash position as it prepares for a potential U.S. regulatory decision later this year.

Summit Therapeutics stock has delivered a very large 3 year gain, but its recent slide and a low overall value score suggest the current price may not line up neatly with the fundamentals that have investors excited about its oncology pipeline. Over the past 3 years, Summit Therapeutics has returned about 7x. This puts the recent 1 year decline of 47.4% and year to date drop of 15.9% into sharper focus for anyone trying to judge what is already priced in. Updated positive Phase III data for...

Summit Therapeutics recently reported updated overall survival results from its global Phase III HARMONi trial, showing that ivonescimab plus platinum-doublet chemotherapy continued to deliver a positive survival trend and consistent safety profile versus chemotherapy alone in both Asian and western patients with advanced EGFR-mutated non-squamous non-small cell lung cancer. The latest analysis brought western patients’ overall survival hazard ratio down to 0.76, aligning the magnitude of...

Summit said it has already shared the latest safety data with the U.S. Food and Drug Administration.

New survival data supports ivonescimab treatmentSummit Therapeutics Inc. (NASDAQ:SMMT) shares gained 3% on Wednesday after the company released updated overall survival data from its global Phase III HARMONi trial evaluating ivonescimab in combination with chemotherapy for advanced lung cancer.

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.

SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.